Citadel Advisors’s Alexza Pharmaceuticals Inc ALXA Stock Holding History

Citadel Advisors’s Portfolio ALXA Stock Details ALXA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-21,244	Closed	-$10K	–	7882
2016 Q1	$10K	Buy	+21,244	New	+$9.29K	﹤0.01%	6598
2015 Q2	–	Sell	-21,327	Closed	-$44K	–	9364
2015 Q1	$44K	Sell	21,327 -4,288	-17%	-$8.8K	﹤0.01%	7465
2014 Q4	$38K	Sell	25,615 -409	-2%	-$730	﹤0.01%	7401
2014 Q3	$61K	Buy	26,024 +14,843	+133%	+$56.7K	﹤0.01%	6781
2014 Q2	$51K	Sell	11,181 -2,010	-15%	-$8.68K	﹤0.01%	6733
2014 Q1	$58K	Buy	13,191 +9,939	+306%	+$51K	﹤0.01%	6660
2013 Q4	$15K	Buy	+3,252	New	+$16K	﹤0.01%	6609
2013 Q3	–	Sell	-1,691	Closed	-$7.96K	–	7009
2013 Q2	$7K	Buy	+1,691	New	+$7.66K	﹤0.01%	6312

Citadel Advisors's ALXA Position: Q2 2016 in Review

Citadel Advisors sold out of Alexza Pharmaceuticals Inc (ALXA) in Q2 2016, closing a stake of 21,244 shares — an estimated $10K sold.

Citadel Advisors first reported a position in ALXA in Q2 2013 and held it in 8 quarters. The position peaked at $61K in Q3 2014. 0 funds tracked by Wall St. Rank hold ALXA as of Q2 2016.

Citadel Advisors reported no remaining Alexza Pharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
Citadel Advisors sold 21,244 Alexza Pharmaceuticals Inc shares in Q2 2016, an estimated $10K.
Citadel Advisors first reported a position in Alexza Pharmaceuticals Inc in Q2 2013 and held it in 8 quarters.
Citadel Advisors's Alexza Pharmaceuticals Inc position peaked at $61K in Q3 2014.
0 funds tracked by Wall St. Rank held Alexza Pharmaceuticals Inc as of Q2 2016.

Based on Citadel Advisors's 13F filing for Q2 2016, filed 12 Aug 2016.